Libtayo
Preclinical
SanofiLibtayo is one of 60 therapeutic programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
51 competitors in Non-Small Cell Lung Carcinoma
#DrugCompanyPhaseTrials
1Lumakras
AmgenApproved
Tabrecta
NovartisApproved
Retevmo
Eli LillyApproved
Rozlytrek
RocheApproved
Keytruda
Merck & Co.Phase 3
Taxol
TevaPhase 3
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tepmetko
EMD SeronoApproved
Abraxane
Bristol-Myers SquibbPhase 3
Imjudo
AstraZenecaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Libtayo. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company